semaglutide heart disease VisualAbstract: improves symptoms in patients with failure Semaglutide and the Heart: Focus

Its designed for cyclical use , not continuous

Batista AF, Bodart-Santos V, De Felice FG, Ferreira ST (2019) Neuroprotective actions of glucagon-like peptide-1 (GLP-1) analogues in Alzheimers and Parkinsons diseases

This highlights the need for further research to distinguish between the risk of developing an autoimmune phenotype and the risk of progressing to severe clinical manifestations like TED. While the research teams findings suggest a protective association between GLP-1 drug therapy and TED, the underlying biological pathways remain speculative

doi: 10.3390/cancers11081086 116 YanTYanNWangPXiaYHaoHWangGet al